The nation of Zimbabwe has declined a substantial American health deal valued at $367m (£272m) over five years because of the United States' insistence on confidential biological samples.
This rejection came to light following a government memo from December was disclosed, which showed Head of State Emmerson Mnangagwa believed the agreement was "skewed".
A government representative later explained that the United States was requesting genetic material for scientific study and profit but was not willing to share the benefits from future vaccines.
"We will now turn to the challenging and unfortunate process of ending our health assistance in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont in a statement.
Her embassy noted the United States had donated more than $1.9bn as health assistance to Zimbabwe during the past twenty years.
A doctors' association in Zimbabwe has urged more talks to secure a agreement agreeable to all parties so the country's vital HIV programme can proceed.
Wider Implications
Zimbabwe's decision comes after a similar case in neighbouring Kenya, where a court halted a similar deal with the US after concerns were filed about the safety of citizens' medical information.
After returning to the presidency recently, US President Donald Trump has slashed foreign aid and closed the key foreign aid agency.
USAID had overseen aid for the American government, but Trump stated its spending was "wasteful" and his government was pursuing direct bilateral agreements to boost transparency and accountability.
According to statements, Sixteen African countries have to date signed similar agreements, constituting over $18.3bn in committed funds.
Details of the Rejected Deal
The money for Zimbabwe was intended to funded "HIV/Aids treatment and prevention, TB, malaria, maternal and child health, and disease outbreak preparedness.
"We are confident this collaboration might have yielded extraordinary advantages for the people of Zimbabwe, particularly the 1.2 million men, women and children presently on antiretroviral therapy through American-funded programmes," Tremont commented.
However, government spokesperson Nick Mangwana maintained the proposed deal was "unfair".
"The proposal required Zimbabwe to provide its genetic material and health information for a long time, with no equivalent assurance of access to any scientific breakthroughs – such as new medicines or tests – that might be developed from that provided information," he stated.
"In essence, our country would provide the raw materials for medical research with no certainty that the resulting innovations would be available to our people if a new disease outbreak emerge."
National Interest and International Frameworks
He also noted that the US's withdrawal from the global health body and its pursuit of one-on-one deals were undermining systems already set up via the global organization.
The spokesperson cited its Pandemic Benefit-Sharing system designed to manage potential global health emergencies.
"This system is designed to ensure that when a nation contributes its samples, the benefits – including medicines and cures – are shared equitably, not commercialised exclusively by those with the resources to create them."
These objections over the US deal "must not be interpreted as anti-American sentiment," he added.
"We are open to ongoing discussions with our US partners on how future co-operation might be arranged in a manner that honours the sovereignty and interests of both nations."
Medical Community Reaction
A leading public health body expressed it acknowledged the government's concerns, but urged that talks must proceed considering a large portion of the nation's Aids initiatives were funded by foreign aid.
"If specific concerns exist, such as those relating to data governance or agreement terms, these can often be addressed via detailed discussion and negotiated safeguards," the group said.
The situation highlights the continuing challenges between receiving much-needed foreign assistance and protecting local interests in an ever more data-driven world.